Group items tagged

Grant WB, Garland CF, Gorham ED. \nAn estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of oral vitamin D per day.\nRecent Results Cancer Res. 2007;174:225-34.\nPMID: 17302200 [PubMed - in process]

Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland CF, Giovannucci E. Epidemic influenza and vitamin D.Epidemiol Infect. 2006 Dec;134(6):1129-40. Epub 2006 Sep 7.PMID: 16959053 doi:10.1017/S0950268806007175

Ecological studies of ultraviolet B, vitamin D and cancer since 2000. Grant WB, Mohr SB. Ann Epidemiol. 2009 Jul;19(7):446-54. Epub 2009 Mar 9. PMID: 19269856 CONCLUSION: These findings provide strong evidence that vitamin D status plays an important role in controlling the outcome of cancer. Support for the UVB-vitamin D-cancer theory is now scientifically strong enough to warrant use of vitamin D in cancer prevention, and as a component of treatment. More research studies would help to explore whether there are benefits beyond the substantial effects that have been observed.

Ecological Studies Of Ultraviolet B, Vitamin D And Cancer Since 2000. Grant WB, Mohr SB. Ann Epidemiol. 2009 Mar 6. [Epub ahead of print] PMID: 19269856 doi:10.1016/j.annepidem.2008.12.014

Feb 23, 2009 (CIDRAP News) - In a development that could create new tools to prevent and treat seasonal and pandemic influenza, researchers have identified and tested human monoclonal antibodies (mAbs) that can neutralize influenza A viruses, including lethal H5N1 avian influenza.\n\nThe findings raise hopes for a universal flu vaccine and shed light on new options for preventing and treating influenza infections, researchers from Dana-Farber Cancer Center, Burnham Institute for Medical Research, and the US Centers for Disease Control and Prevention (CDC) reported yesterday in an early online edition of Nature Structural and Molecular Biology. The study was supported by a grant from the National Institute of Allergy and Infectious Diseases (NIAID).

ScienceDaily (May 12, 2009) - Taking folic acid supplements for at least a year before conception is associated with reduction in the risk of premature birth, according to a study by Radek Bukowski (from the University of Texas Medical Branch, United States of America) and colleagues. Although most pregnancies last about 40 weeks, many babies (for example around 12% in the United States) are born before 37 completed weeks of pregnancy. Babies born prematurely are less likely to survive than full-term babies and are more likely to have breathing difficulties and learning or developmental disabilities. Currently, there are no effective methods of prevention or treatment of premature (preterm) birth, but previous studies have suggested that lower concentrations of folate (folic acid) are associated with shorter duration of pregnancy. Bukowski and colleagues therefore tested this idea, by analyzing data collected from a cohort of nearly 35,000 pregnant women. The results of this study showed that taking folate supplements for at least one year before conception was associated with a 70% reduction in spontaneous premature birth between 20 and 28 weeks (a reduction from 0.27% to 0.04%), and a 50% reduction between 28 and 32 weeks (reduction from 0.38% to 0.18%), as compared to the rate of preterm birth when mothers did not take additional folate supplementation. Folate supplementation for less than a year before conception was not linked to a reduction in the risk of premature birth in this study, and folate supplementation was not associated with any other complications of pregnancy. In a related commentary also published in this week's PLoS Medicine, Nicholas Fisk from the University of Brisbane, Australia, and colleagues (who were not involved in the original study) say "Methodologically, the study has several strengths... It is based on a huge dataset, with prospective recording of dietary supplements and potential confounders, and gestational age determined accu

see more articles reviewed on my blog: drjohndc.tumblr.com

ScienceDaily (May 12, 2009) - The more pills a dialysis patients takes, the worse their health-related quality of life, according to a new study. The findings indicate that increasing the number of medications to control patients' disease may interfere with their ability to enjoy normal activities. Kidney disease patients undergoing dialysis must take more pills than most patients with other chronic diseases. While these medications are important for controlling patients' disease, at some point taking too many pills (with their ensuing side effects) may negatively affect patients' health-related quality of life, or their perceived physical and mental health. Rajnish Mehrotra, MD and Yi-Wen Chiu, MD (Los Angeles Biomedical Research Institute), and their colleagues conducted a study to see if "pill burden" affects dialysis patients' health-related quality of life. They studied 233 chronic dialysis patients from three clinics in different geographic areas in the United States. The investigators found that patients took an average of 19 pills a day and that a quarter of the patients took more than 25 pills a day. Patients with a high pill burden had lower perceived physical health. Medications called phosphate binders, which control the level of phosphorous in the blood, accounted for about half of the daily pill burden. Sixty-two percent of the patients did not take these medications as directed. The more phosphate binders a patient was prescribed, the less likely they were to take their medications as directed and the less likely they were to have their blood phosphorous levels under control. These findings indicate that increasing the number of prescribed pills does not seem to improve control of phosphorous levels and may come at the cost of poorer health-related quality of life. The authors note that any attempts to tackle dialysis patients' pill burden must address the number of phosphate binders a patient is prescribed on a daily basis. Dr. Mehrotra has re